Winst gevend schreef op 18 juni 2020 17:14:
Beste nieuws voor Pharming komt van de concurrentie:
Patient-reported attack history shows patients treated with current injectable or infused prophylactic medications (Takhzyro®, Haegarda®, Cinryze®) continue to experience breakthrough attacks with a mean ranging from 0.9 to 1.8 attacks over the three months prior to survey.
In addition, the majority of patients surveyed did not expect to have zero attacks even when taking prophylaxis therapy.
The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress.